Table 3. Overall survival (in months) by demographic characteristics.
| Characteristic | n | Median | 95% CI | P-value |
|---|---|---|---|---|
| Overall | 46 | 18.3 | 13.7, 25.9 | |
| Age group | 0.44 | |||
| <60 | 22 | 20.5 | 14.5, 31.4 | |
| ≥60 | 24 | 14.7 | 9.5, 25.9 | |
| Country | 0.21 | |||
| France | 21 | 17.0 | 7.8, 25.9 | |
| USA | 25 | 19.4 | 13.7, NA | |
| Gender | 0.83 | |||
| Female | 24 | 19.4 | 10.9, 30.7 | |
| Male | 22 | 18.1 | 14.5, 25.9 | |
| Ethnicity | 0.10 | |||
| African descent | 3 | 13.7 | 4.4, 18.3 | |
| Non African descent | 43 | 19.4 | 13.4, 26.4 | |
| Performance status | 0.29 | |||
| 0 | 30 | 18.3 | 13.4, 25.9 | |
| 1–2 | 16 | 16.1 | 10.2, NA | |
| Tumour size | 0.23 | |||
| <3 cm | 15 | 16.1 | 10.9, 20.5 | |
| ≥3 cm | 27 | 19.4 | 13.7, 45.7 | |
| Nodal status | 0.15 | |||
| Negative | 13 | 30.7 | 13.7, NA | |
| Positive | 30 | 15.4 | 9.7, 20.5 | |
| Stage | 0.07 | |||
| T1,2 | 12 | 30.7 | 18.3, NA | |
| T3,4 | 32 | 14.6 | 10.2, 20.9 |
NA, not applicable